FleuryBSP:FLRY3 +4.25%90 Receivables Turnover is 1.18 as of Mar. 2026. GuruFocus rates BSP:FLRY3 with a GF Score™ of 90/100 and a GF Value™ of R$17.47 (Fairly Valued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Fleury ranks worse than 61.08% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Fleury's Revenue for the
three
months ended in Mar. 2026 was R$2,223 Mil. Fleury's average Accounts Receivable for the
three
months ended in Mar. 2026 was R$1,877 Mil.
Hence, Fleury's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.18.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Fleury Receivables Turnover Related Terms
Fleury Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Fleury's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:FLRY3 vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Fleury's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fleury Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fleury's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Fleury's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fleury (BSP:FLRY3) has a Receivables Turnover of 1.18 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Fleury and its competitors. According to the industry distribution chart, Fleury ranks #124 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 61.1%.
Is Fleury's Receivables Turnover too high?
Fleury's current Receivables Turnover is 1.18. The Medical Diagnostics & Research industry median Receivables Turnover is 5.37. Fleury's value of 1.18 is 78% below this industry median. Based on the distribution chart, Fleury ranks #124 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Fleury has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fleury's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Fleury ranks #124 out of 203 companies for Receivables Turnover. This places Fleury in the lower half of its industry. The industry median Receivables Turnover is 5.37. Fleury's value of 1.18 is 78% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.37, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fleury's current Receivables Turnover of 1.18 is 78% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Fleury and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fleury's current Receivables Turnover is 1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fleury stock overvalued right now?
Based on GuruFocus' analysis, Fleury (BSP:FLRY3) is currently considered Fairly Valued. The stock's GF Value™ is R$17.47, compared to a current price of R$16.42 — trading 6% below its estimated fair value. The current Receivables Turnover is 1.18 and 78% below the Medical Diagnostics & Research industry median of 5.37. Fleury's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Fleury (BSP:FLRY3), the current Receivables Turnover is 1.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fleury (BSP:FLRY3) Overvalued in 2026?
Based on GuruFocus' analysis, Fleury stock appears to be undervalued.
The current stock price of R$16.42 is trading 6% below its estimated GF Value™ of R$17.47.
GuruFocus considers Fleury to be Fairly Valued.
Key valuation signals for BSP:FLRY3:
Receivables Turnover: 1.18
GF Value™: R$17.47 vs. price of R$16.42 (6% below fair value)
Industry Position: 78% below the Medical Diagnostics & Research median (#124 of 203)
No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
90GF Score
Get the complete analysis for BSP:FLRY3
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:FLRY3 has been successfully added to your 
